Patents by Inventor Andy Weinberg

Andy Weinberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer treatment and monitoring methods using OX40 agonists
    Patent number: 9828432
    Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: November 28, 2017
    Assignee: PROVIDENCE HEALTH & SERVICES—OREGON
    Inventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg
  • DUAL OX40 AGONIST/IL-2 CANCER THERAPY METHODS
    Publication number: 20150157710
    Abstract: OX40 is a potent immune stimulating target. Provided herein is a method of treating cancer, which includes administering to a subject in need of treatment an OX40 agonist and a common gamma chain (yc) cytokine or an active fragment, variant, analog, or derivative thereof. In certain aspects the common gamma chain (yc) cytokine is interleukin-2 (IL-2) or an active fragment, variant, analog, or derivative thereof. Combined treatment with an agonist anti-OX40 mAb and IL-2 synergized to augment tumor immunotherapy against multiple tumor types. Dual therapy was also able to restore the function of anergic tumor-reactive CD8+ T cells.
    Type: Application
    Filed: March 2, 2012
    Publication date: June 11, 2015
    Applicant: Providence Health & Services-Oregon d/b/a Providence Portland Medical Center
    Inventors: William Redmond, Andy Weinberg
  • CANCER TREATMENT AND MONITORING METHODS USING OX40 AGONISTS
    Publication number: 20150098942
    Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.
    Type: Application
    Filed: February 6, 2012
    Publication date: April 9, 2015
    Applicant: Providence Health & Services - Oregon d/b/a Providence Portland Medical Center
    Inventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg